Boston Scientific (BSX) is drawing investor attention after its recent share move, with the stock closing at $52.01 on 18 August 2026. That price shift puts fresh focus on how its medical device business supports current valuation.

Over the past month Boston Scientific has seen a strong 30 day share price return of 18.83%, although the share price is still down 45.08% year to date and the 1 year total shareholder return is down 50.96%. This indicates that recent momentum is rebuilding from a weaker longer term base.

If you are reassessing healthcare exposure after Boston Scientific's recent move, it can be useful to see what else is gaining attention in the sector through the 42 healthcare AI stocks

After a sharp rebound yet still heavy longer term declines, Boston Scientific now asks a simple question of investors: Does the current price fairly capture the risk around its medical device earnings stream, or still leave upside for new buyers?

Most Popular Narrative: 28% Undervalued

On the most followed narrative, Boston Scientific's fair value of $72.25 sits well above the recent $52.01 close, which puts the current share price at a sizeable discount in that framework.

Investment in proprietary, high-margin technologies (e.g., next-gen mapping, advanced diagnostic tools, differentiated urology/neuromodulation pipelines) combined with successful integration of recent acquisitions (Axonics, SoniVie, Intera, Silk Road) expands Boston Scientific's addressable market and is likely to drive margin expansion as product mix improves.

Enhanced scale and operational efficiency through supply chain initiatives, digitalization, and manufacturing automation alongside robust cash flow positions Boston Scientific to expand operating margins and generate sustainable earnings growth over the long term.

Want to see what sits behind that higher fair value for Boston Scientific? The narrative leans on specific revenue, margin and earnings paths that could reshape the long term earnings base.

Result: Fair Value of $72.25 (UNDERVALUED)

However, the outlook for Boston Scientific could change quickly if Watchman and electrophysiology demand stays weaker for longer or if reimbursement cuts hit procedure volumes harder than expected.

Next Steps

With sentiment on Boston Scientific split between concern and optimism, it makes sense to review the numbers now and form your own view using the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Boston Scientific?

If Boston Scientific has you rethinking your next move, do not stop with one stock. Use focused screeners to uncover ideas that match your goals before the market moves.

• Target potential value opportunities by checking companies that currently screen as 52 high quality undervalued stocks.
• Strengthen your downside protection by focusing on 78 resilient stocks with low risk scores.
• Get ahead of the crowd by reviewing a screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.